Navigation Links
Obesity Drug Advertisements Misleading Teens

Advertisements for the weight loss drug Xenical has come under criticism from consumer watchdog, Choice saying that it is misleading young teenage girls//, preying on their fears about their bodies in a breach of advertising guidelines.

The ads have been screened during the high-rating Australian Idol program whose major audiences include 13- to 17-year-olds and have reportedly driven teens as young as 13 and of average weight to seek out the drugs from pharmacies.

Choice said that the ads breached the Therapeutic Goods Advertising Code Council's guidelines prohibiting drug advertising that are directed at people under 18. It has set the call for the withdrawal of the campaign.

Pharmacists have reported increased demands from customers of average weight during the two weeks since the drug has been directly advertised.

One pharmacist on an industry email list wrote, ‘Am I the only one who's noticed a sudden incidence, since the branded advertising started, of people requesting Xenical who have a [body mass index] of 25 or less?’.

"These [mainly female] patients look like they have a healthy weight, yet they're all telling me they want to lose another 5 to 10 kilograms."

Another pharmacist wrote: "I think we are going to be spending a lot of our time sorting out the few people for whom Xenical might be useful from the many who decide they want it, following promotion direct to consumer." However some others have considered that it would do no harm to provide the drug to those with a healthy weight, in spite of its known side effects such as diarrhea and incontinence.

Viola Korczak, the health policy officer at Choice said that the safety and efficacy of Xenical for children had not been established, adding, "Our concern is that parents may not even know that their children are taking these drugs."

Channel Ten markets Australian Idol as the place for advertisers to reach the youth and says the pro
'"/>




Page: 1 2

Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Obesity raises IVF miscarriage risk
3. Obesity a risk for pancreatic cancer
4. Obesity shortens lifespan
5. Is Obesity a risk factor?
6. Obesity a global problem
7. Obesity increases health costs
8. Obesity in children a risk factor for diabetes
9. Decrease of Hunger Hormone after Obesity Surgery
10. Obesity risk for immobilized adults
11. Obesity risk can be reduced by eating breakfast regularly

Post Your Comments:
(Date:12/2/2009)...PRNewswire-FirstCall/ -- Gen-Probe Incorporated (N...er Jaffray Health Care Conference today at 2:30 p....be webcast live and may be accessed through a link...t www.gen-probe.com . The webcast will be availab...en-Probe ,, Gen-Probe Incorporated is a globa...
(Date:12/2/2009)...ewswire/ -- A randomized, controlled study compari...vasive treatment called percutaneous disc decompre...le both treatments help patients in the short run,...p to two years later. Results of the study, the fi...l meeting of the Radiological Society of North Ame...
(Date:12/2/2009)...2 LeapFrog Investments has announc... in AllLife, the innovative South African insurer ...nvestment brings together LeapFrog, the leading mi...Africa,s most innovative insurance businesses. The..., "AllLife has developed a distinctive and profit...
(Date:12/2/2009)...sound of suspicious areas of the breast, including...ernative to invasive biopsies for women under age ...nted today at the annual meeting of the Radiologic...ming high-quality breast ultrasound, we can reduce...agnostic procedures in young women," said senior a...
(Date:12/2/2009)...ale clinical trial presented today at the annual m...a (RSNA) provide the first strong evidence of the ...ith dense breasts who are at elevated risk for bre...MRI is highly sensitive in depicting early breast ...ltrasound in addition to mammography significantly...
Breaking Medicine News(10 mins):Health News:Gen-Probe to Webcast Presentation at the 21st Annual Piper Jaffray Health Care Conference Today 2Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 2Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 3Health News:LeapFrog Invests $6M in AllLife, Innovative African HIV and Diabetes Insurer 2Health News:LeapFrog Invests $6M in AllLife, Innovative African HIV and Diabetes Insurer 3Health News:Targeted breast ultrasound can reduce biopsies for women under 40 2Health News:Annual screening with breast ultrasound or MRI could benefit some women 2
...8 Kensey Nash Corporation (Nasdaq: KNSY ) today...d a stock repurchase. The new program allows the ...its issued and outstanding shares of Common Stock ...he recent trading price of our stock, we believe w...
...ey asks adults what lessons they learned from elde...e; top response was gratitude; elders say that sim...r key lessons: perseverance, importance of family ...conjunction with national conference Aging in Amer...
...Cells to Be Harvested and Transplanted Into the Ja...al Implantation , , RANCHO SANTA MARGARITA, Calif...o restore his infectious grin, but to attach an im...ental, will make Morgan,s wish come true through t...
...., March 18 In the eight years since its inceptio...nter in Evergreen Park, Illinois, has developed a ...omeo, R.N., CNOR, CRNFA, the bariatric surgery pro...t who undergoes weight-loss surgery at the Little ...
... March 18 Ribbit Marketing, Inc. is hosting a tel...for North Carolina college film students to increa...re being requested for PSAs showcasing www.NCHeal...lina. , , The PSA contest will give students the...
...f Sales to the Northern California Chapter of the ...rch 18 Presto Services Inc. announces a specia...Month in March to raise funds and awareness to fin... 5% of the retail value ($7.49 each) to the North...
Other Medicine News:Health News:Kensey Nash Announces 600,000 Share Stock Repurchase Program 2Health News:Kensey Nash Announces 600,000 Share Stock Repurchase Program 3Health News:New Survey: Top Lesson from Seniors About Economic Worries? Gratitude Trumps Fear 2Health News:Southern California Dentist First on the West Coast to Perform Concentrated Stem Cell Transplant for Dental Implant Procedure 2Health News:Southern California Dentist First on the West Coast to Perform Concentrated Stem Cell Transplant for Dental Implant Procedure 3Health News:Chicago-area ASBS Bariatric Surgery Center of Excellence Provides Personalized Care Like No Other Weight-Loss Surgery Program 2Health News:Ribbit Marketing Hosts Contest for NC Film Students 2Health News:Presto Announces Donation Program to Help Find the Cure for Multiple Sclerosis 2Health News:Presto Announces Donation Program to Help Find the Cure for Multiple Sclerosis 3
(Date:12/2/2009)... , EAST HANOVER, N.J., Dec. 2 N... late-breaking presentation on Tasigna® (nilo...d leukemia, demonstrate the strength of the compan...patients. ,, The new data, at the 51st America...xposition, highlight the company,s current therapi...
(Date:12/1/2009)...MECULA, Calif., Dec. 1 P...rd: PSTX) announced today that it has appointed Ma...ncial Officer, Treasurer and Corporate Secretary, ...ce 2008. Prior to joining Patient Safety Technolo...hief Financial Officer, Treasurer and Corporate Se...
(Date:12/1/2009)...ONDO BEACH, Calif., Dec. 1 Reprodu... Elective Single Embryo Transfer (eSET) Encouragem...atients with good embryo quality and a good progno... twins by transferring a single embryo. ,, The ...today is reducing the number of multiple pregnanci...
Breaking Medicine Technology:Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Patient Safety Technologies, Inc. Appoints Marc L. Rose, CPA (PA), Chief Financial Officer 2Reproductive Partners Announces Elective Single Embryo Transfer (eSET) Encouragement Program 2CareTech Expands Services to Garden City Hospital With Radiology Workflow Technology 54843 1CareTech Expands Services to Garden City Hospital With Radiology Workflow Technology 54843 2CareTech Expands Services to Garden City Hospital With Radiology Workflow Technology 54843 3eDiets com 28R 29 Granted Continued Listing by NASDAQ Panel 54840 1eDiets com 28R 29 Granted Continued Listing by NASDAQ Panel 54840 2Are You Connected 3F AIM and GASICORP Expand Global Reach Through Landmark Strategic Alliance 54836 1Are You Connected 3F AIM and GASICORP Expand Global Reach Through Landmark Strategic Alliance 54836 2Are You Connected 3F AIM and GASICORP Expand Global Reach Through Landmark Strategic Alliance 54836 3
...lif.--(BUSINESS WIRE)--Apr 18, 2007 - Avanir,Pharm...top-line,results from the company,s Phase III clin...via(TM) (dextromethorphan,hydrobromide/quinidine s...onist, in diabetic neuropathic pain., The primary ...,entries for the Pain Rating Scale as defined in t...
...with a Bavituximab Equivalent and Irradiated Tumor... in Controls in a,Preclinical Model of Brain Cance...7,/PRNewswire-FirstCall/ -- Peregrine Pharmaceutic...pany developing targeted,monoclonal antibodies for...V) infection, today announced preclinical studies,...
Other Medicine Technology:Avanir Pharmaceuticals Announces Positive Results of Phase III,Study for Zenvia in Diabetic Neuropathic Pain 2Avanir Pharmaceuticals Announces Positive Results of Phase III,Study for Zenvia in Diabetic Neuropathic Pain 3Avanir Pharmaceuticals Announces Positive Results of Phase III,Study for Zenvia in Diabetic Neuropathic Pain 4Avanir Pharmaceuticals Announces Positive Results of Phase III,Study for Zenvia in Diabetic Neuropathic Pain 5Avanir Pharmaceuticals Announces Positive Results of Phase III,Study for Zenvia in Diabetic Neuropathic Pain 6Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 2Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 3Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 4Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 5Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 6
...c has been a key participant in the area of blood ...us Medtronic autotransfusion systems allowed clini...latelets, as well as to determine requirements for...ch plasma (PRP) for a small amount of autologous b...
RX HERCULINK® PLUS Biliary Stent System
Response Catheter
Fast-Cath™ Guiding Introducers
Medicine Products: